Skip to content
PeptideAgent

Compounding pharmacies in Kentucky

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Kentucky Board of Pharmacy regulates compounding pharmacies in Kentucky. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Kentucky at a glance

Pharmacy regulator
Kentucky Board of Pharmacy
503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Kentucky

No verified compounding pharmacies serving Kentucky are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Kentucky

The Kentucky Board of Pharmacy regulates pharmacies under KRS chapter 315 and Title 201, chapter 2 of the Kentucky Administrative Regulations. Kentucky follows the federal 503A framework for which bulk substances may be compounded, and 201 KAR 2:076 (compounding) incorporates the federal essentially-a-copy limit into state law by prohibiting compounding of essential copies of a commercially available drug product unless authorized by 21 U.S.C. 353a, which the Board says it enforces against every Kentucky licensee and permit holder. Out-of-state pharmacies that ship dispensed drugs to Kentucky patients must hold a Kentucky out-of-state pharmacy permit. KRS 315.0351 requires every pharmacy outside Kentucky that does business in the state, physically or by internet, phone, mail, or other means, to hold an out-of-state pharmacy permit from the Board, disclose its principal officers and dispensing pharmacists annually, keep its home-state license valid, and file its most recent home-state inspection report before applying and each later report after. [1] [2] [3] [4] [6]

Compounded GLP-1 access in Kentucky

The Kentucky Board of Pharmacy's 2025 guidance, "Important Update: Compounding Semaglutide and Tirzepatide," states that in general compounding pharmacies may not compound semaglutide or tirzepatide because they are commercially available, that adding another ingredient such as B12 does not avoid the essentially-a-copy rule, that a lower price is not a valid reason, and that noncompliant compounding may lead to action by both FDA and the Board. The narrow exceptions are a documented patient-specific change that produces a significant difference for that patient, or a return of the drug to the FDA shortage list. [2] [3] [9]

Research use only sellers in Kentucky

Only Kentucky-permitted pharmacies may dispense prescription drugs to Kentucky patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and fall outside Kentucky's compounding regulation. The Kentucky Food, Drug and Cosmetic Act, KRS 217.075, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has become effective under the federal act; its investigational exemption covers only drugs intended solely for investigational use by qualified experts and labeled for investigational use only. [1] [5] [10]

Kentucky notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies in general may not compound semaglutide, and 201 KAR 2:076 makes the essentially-a-copy prohibition enforceable by the Board; adding B12 does not change that. [2] [3]
  • Tirzepatide: Available branded by prescription. The same Kentucky guidance covers tirzepatide: 503A compounding under the shortage allowance ended in 2025, and compounded copies are allowed only for a documented significant patient-specific difference. [2] [9]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. Because it is not commercially available, the essentially-a-copy rule does not apply to it; Kentucky pharmacies apply the federal bulks eligibility test. [3] [7] [8]

How to check a compounding pharmacy in Kentucky

  1. Search the Kentucky Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Kentucky requires before it ships to you. [1] [2] [3] [4] [6]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Kentucky. [1] [5] [10]

Common questions in Kentucky

Can Kentucky pharmacies compound semaglutide or tirzepatide?

In general, no. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies may not compound semaglutide or tirzepatide because both are commercially available, and 201 KAR 2:076 lets the Board enforce the federal essentially-a-copy ban. The exceptions are a documented patient-specific change that makes a significant difference for that patient, or a return to the FDA shortage list. [2] [3]

Does adding B12 to compounded semaglutide make it legal in Kentucky?

No. The Kentucky Board's guidance repeats FDA's position that a compounded product containing the same active ingredients as commercially available drugs, such as semaglutide plus B12, is still essentially a copy unless the prescriber documents a patient-specific need. [2]

What does an out-of-state pharmacy need to ship compounded peptides to Kentucky?

A Kentucky out-of-state pharmacy permit from the Kentucky Board of Pharmacy, and any compounded product must still comply with 201 KAR 2:076. Check the Board's license verification before ordering. [1] [3] [4]

All peptide legal questions for Kentucky

Sources

  1. [1]Kentucky Board of Pharmacy
  2. [2]Kentucky Board of Pharmacy: Important update, compounding semaglutide and tirzepatide (2025)2025
  3. [3]201 KAR 2:076, Compounding (Kentucky Board of Pharmacy)
  4. [4]KRS 315.0351, Out-of-state pharmacy permit (Kentucky Legislative Research Commission)
  5. [5]KRS 217.075, Restrictions on handling of new drugs (Kentucky Food, Drug and Cosmetic Act)
  6. [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  7. [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  8. [8]FDA: Pharmacy Compounding Advisory CommitteeFDA
  9. [9]FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeFDA
  10. [10]21 U.S.C. 331, Prohibited acts